The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Biopharmaceutical benchmarks 2018
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“between 2014 and 2018 the vast majority (84%) of newly approved antibody therapeutics were produced in CHO cells [5].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [5]
In the citing paper
“Coming back to Ig-based biotherapeutics, atezolizumab, an oncolytic anti-PD-L1 mAb, is another clinically approved (2016-US, 2017-EU) glycoengineered product, except the Fc has been engineered to lack glycosylation [5].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [5]
In the citing paper
“CHO cells have become dominant in biotherapeutic production because they produce non-immunogenic and near human-like glycosylation [5].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [5]
Citations
Cites
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76
Research works printed but not linked: 11
- Walsh, G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32, 992–1000 (2014). · DOI · Paper page
- Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010). · DOI
- Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769–776 (2006). · DOI
- Bertolini, L.R. et al. The transgenic animal platform for biopharmaceutical production. Transgenic Res. 25, 329–343 (2016). · DOI
- Park, T.S. et al. Deposition of bioactive human epidermal growth factor in the egg white of transgenic hens using an oviduct-specific minisynthetic promoter. FASEB J. 29, 2386–2396 (2015). · DOI
- Miliotou, A.N. & Papadopoulou, L.C. CAR T-cell therapy: a new era in cancer immunotherapy. Curr. Pharm. Biotechnol. 19, 5–18 (2018). · DOI
- Kaplon, H. & Reichert, J.M. Antibodies to watch in 2018. MAbs 10, 183–203 (2018). · DOI
- Zheng, P.P., Kros, J.M. & Li, J. Approved CAR-T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today 23 1175–1182 (2018). · DOI
- Labanieh, L., Majzner, R.G. & Mackall, C.L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377–391 (2018). · DOI
- Köhl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29, 559–568 (2018). · DOI
- Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE® antibody constructs—past developments and future directions. Immunol. Rev. 270, 193–208 (2016). · DOI
Cited by
Sorted by citations
High-Resolution Native Mass Spectrometry
Tamara, S., den Boer, M. A., & Heck, A. J. R. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00212 · Cited by 511
Tripathi, N. K., & Shrivastava, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00420 · Cited by 621
“%) were from mammalian cells, one from a transgenic system, five from E. coli, and four from S. cerevisiae (Walsh, 2018).”
BackgroundInfluentialBiopharmaceutical benchmarks 2022
Walsh, G., & Walsh, E. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01582-x · Cited by 603
Self-citationRecent advancements in the genetic engineering of microalgae
Sproles, A. E., Fields, F. J., Smalley, T. N., Le, C. H., Badary, A., & Mayfield, S. P. (2021) · Algal Research · doi:10.1016/j.algal.2020.102158 · Cited by 228
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 300
“They represent six of the top ten selling drugs (7) with annual sales exceeding $120 billion in 2017 (8) and are expected to reach $130–200 billion by 2022 (9).”
Background
Metadata
- Authors
- Walsh, G.
- Affiliations
- University of Limerick (IE)
- Corresponding author
- Walsh, Gary
- ORCID
- Walsh, Gary
- Venue
- Nature Biotechnology
- Published
- 2018-12
- Volume
- 36
- Issue
- 12
- Pages
- 1136-1145
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2917928050
- Cited by
- 978
- References
- 15
- Citations by year
- 2026: 68 · 2025: 68 · 2024: 88 · 2023: 141 · 2022: 173 · 2021: 197 · 2020: 173 · 2019: 65
- FWCI
- 165.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- biopharmaceutical market, monoclonal antibodies, cell therapy, gene therapy, biosimilars, biologics, market growth
- MeSH terms
- Animals, Antibodies, Monoclonal, Biological Products, Biotechnology, Drug Industry, European Union, Humans, Nucleic Acids, Recombinant Proteins, United States, United States Food and Drug Administration, Drug Approval, Benchmarking, Biosimilar Pharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
